Aeglea BioTherapeutics, Inc.(AGLE) - 2025 Q3 - Quarterly Results

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA") Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update O ...